aTyr Pharma, Inc.(US:ATYR) Prnewswire·2025-10-30 12:45Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the efficacy of its drug Efzofitimod, which failed to meet its primary endpoint in a clinical study, leading to a significant drop in stock price [1]. Group 1: Allegations and Impact - The lawsuit claims that aTyr Pharma made overwhelmingly positive statements about Efzofitimod while concealing material adverse facts about its efficacy, particularly regarding the drug's ability to allow patients to taper off steroids completely [1]. - The EFZO-FIT study did not meet its primary endpoint, specifically in the change from baseline in mean daily OSC dose at week 48, which was disclosed during an investor call on September 15, 2025 [1]. - Following the announcement, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking a decline of 83.2% in just one day [1]. Group 2: Class Action Details - Shareholders who purchased shares of aTyr during the class period from January 16, 2025, to September 12, 2025, are encouraged to register for the class action lawsuit, with a deadline for lead plaintiff appointment set for December 8, 2025 [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case, with no cost or obligation to participate [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered losses due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by false or misleading statements that led to artificial inflation of stock prices [3].